Patent EP-2457575-A1 (EP)
Inventor: KRUSZEWSKA DANUTA
IPC: A61K35/74
Filed: 2010-11-29
Abstract: The invention related to a antimicrobial agent being a  Lactobacillus reuteri  DAN080 culture, a partially inactivated  L. reuteri  DAN080 culture, liquid supernatant of  L. reuteri  DAN080 culture, concentrated supernatant  of L. reuteri  DAN080 culture, and dried supernatant of  L. reuteri  DAN080 culture, for the prophylaxis and treatment of medical conditions developing as a result of infections caused by bacteria, fungi, and other pathogens of the gastrointestinal tract, body surface, and other systems, such as urogenital system, respiratory system, in vertebrates. 
     An antimicrobial agent selected from the group comprising the whole  L. reuteri  DAN080 culture, liquid supernatant, concentrated supernatant, and dried supernatant obtained from  L. reuteri  DAN080 culture and from mixed bacterial cultures, containing  L .  reuteri  DAN080, and liquid supernatants, concentrated supernatants and dried supernatants obtained from the cultures of prokaryotic and eukaryotic recombinants, and the whole cultures of prokaryotic and eukaryotic recombinants, in which and/or from which genes are utilized, which genes provide specific modulatory, inhibitory, and homeostatic activity with respect to  H. pylori  and other bacteria; proteins/oligopeptides/peptides of molecular weight of approximately: 150 and/or 141 and/or 115 and/or 95 and/or 90 and/or 86 and/or 83 and/or 77 and/or 71 and/or 63 and/or 59 and/or 56 and/or 49 and/or 46 and/or 43 and/or 39 and/or 34 and/or 32 and/or 30 and/or 22 kD, or lower, purified/isolated from liquid, concentrated, dried supernatants, obtained from  L. reuteri  DAN080, and purified/isolated from the whole  L. reuteri  DAN080 cultures, and from other mixed bacterial cultures, which included  L. reuteri  DAN080, and from purified or isolated cultures of prokaryotic and eukaryoticrecombinants, in which and/or from which genes are utilized, which genes provide specific modulatory, inhibitory, and homeostatic activity with respect to  H. pylori  and other bacteria or their mixtures, for the prophylaxis and treatment of medical conditions developing as a result of infections caused by bacteria, fungi, and other pathogens of the gastrointestinal tract, body surface, and other systems, such as urogenital system, respiratory system, in vertebrates. 
     This agent of the invention is used for the more effective killing, inhibition, regulation and prevention of the growth of  H. pylori  and other bacteria, and is used for obtaining an improvement in GIT disorders, gastritis, gastric ulcer, duodenal ulcer, gastric cancer, and duodenal cancer in vertebrates, including mammals and birds, by administration to vertebrates, including mammals and birds, of an effective amount, and possibly, at an appropriate rate to allow obtaining the desired results of the antimicrobial agent. 
     This agent is used for the manufacturing of compositions, such as pharmaceutical compositions, dietary supplements, food products, beverages, as well as feed and feed additives useful in the method of therapeutic or preventive modulation of gastritis and other related diseases, e.g. gastric and duodenal ulcer, gastric and duodenal cancer, intestinal disorders, GIT disorders and diarrhoea in vertebrates, including mammals and birds.